ClinicalTrials.gg
TerminatedNCT02685267Doce/EnzaUpdated Apr 9, 2021Results posted

Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer

A Phase 2 interventional study of Docetaxel and Enzalutamide in Prostate Cancer, sponsored by Prostate Cancer Clinical Trials Consortium. Terminated at 5 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-09.

Sponsored by Prostate Cancer Clinical Trials Consortium · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

This is a prospective randomized phase II clinical trial where patients who are receiving enzalutamide in the pre-chemotherapy space are randomized upon objective progression (radiographic and/or clinical per PCWG2 criteria) to docetaxel/prednisone alone or the same combination plus enzalutamide.

The primary aim is to evaluate whether continuing enzalutamide in combination with docetaxel in patients who failed or progressed while on enzalutamide would increase progression-free survival (PFS) by 4 months. The secondary end points are PSA responses, percent of patients alive at 1 and 2 years, decline in circulating tumor cells (CTCs), and quality of life (QOL) using validated scales.

02

Conditions studied

  • Prostate Cancer

Browse trials for

03

In context

Prostatic Neoplasms

7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.

This study's enrollment of 9 is below the median of 60 across 5,348 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Prostate Cancer Clinical Trials Consortium is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide written and HIPAA authorization for the release of personal health information.

NOTE: HIPAA authorization may be either included in the informed consent or obtained separately.

  • Males 18 years of age and above
  • or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
  • Having documented disease progression on enzalutamide defined by 1 or more of the following criteria:
  • PSA progression according to PCWG2 criteria with 3 consecutive rising PSA measurements, all collected at least 1 week apart
  • Radiographic progression in soft tissue or bone by modified 1.1 for subjects with ; or
  • Bone disease progression defined by 2 or more new lesions on 2 consecutive bone scans in the absence of falling PSA
  • Patients who have not had a bilateral orchiectomy must have a plan to maintain effective GnRG-analogue therapy for the duration of the trial
  • Serum testosterone level \< 50 ng/dL at Screening visit
  • PS: 0-1
  • Throughout the study, male patients and their female partners of must use 2 acceptable methods of (1 of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administration. Two acceptable methods of birth control thus include the following:
  • Condom (barrier method of contraception even if having sex with a pregnant woman)
  • One of the following is required:

    • Established use of oral, injected, or implanted hormonal method of contraception by the female partner
    • Placement of an intrauterine device (IUD) or intrauterine system (IUS) by the female partner
    • Additional barrier method: Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository by the female partner
    • Tubal litigation in the female partner
    • Vasectomy or other procedure resulting in infertility (eg, bilateral orchiectomy) for >6 months
  • Patients must have adequate organ and marrow function as defined below
  • Leukocytes >3,000/mm3
  • >1,500/mm3
  • >100,000/mm3
  • total within normal institutional limits (or \<2X the in those with Gilbert's disease)
  • (SGOT)/ALT(SGPT) \<1.5 X institutional upper limit of normal
  • creatinine within normal institutional limits OR
  • * >45 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
  • Estimated of > 6 months
  • Able to swallow the study drug as prescribed and comply with study requirements

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with docetaxel-based chemotherapy
  • Prior treatment with abiraterone acetate
  • Prior treatment with cabazitaxel
  • Severe concurrent disease, infection, or co-morbidity that, in the judgment of the Investigator, would make the patient inappropriate for enrollment
  • Ongoing treatment
  • Medical conditions such as uncontrolled hypertension, uncontrolled diabetes mellitus, cardiac disease that would, in the opinion of the investigator, make this protocol unreasonably hazardous
  • Major surgery within 4 weeks of enrollment
  • Use of an investigational therapeutic agent with 4 weeks of enrollment
  • History of seizure or any condition that may predispose to seizure.
  • History of loss of consciousness or within 12 months of enrollment
  • Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease) within last 3 months
  • Grade > 2 treatment-related toxicity from prior therapy
  • History of to polysorbate 80
  • Any known allergy to the compounds under investigation
  • Any other condition which, in the opinion of the Investigator, would preclude participation in this trial
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Active comparator
    Docetaxel/Prednisone

    Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout

    Drug: Docetaxel · Drug: Prednisone

  • Active comparator
    Docetaxel/Prednisone + Enzalutamide

    Docetaxel 75 mg/m2 day 1 (every 21-days) plus prednisone 5 mg po bid throughout plus Enzalutamide 160 mg daily throughout. Subjects will continue enzalutamide until PD after 10 cycles of docetaxel.

    Drug: Docetaxel · Drug: Enzalutamide · Drug: Prednisone

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (Radiographic or Per PCWG2 Criteria)

    The primary endpoint of the study is progression-free survival (PFS), defined as the time from randomization to disease progression. Progression will be evaluated using a combination of RECIST and Prostate Cancer Working Group 2 guidelines.

    Time frame: 1 year

Secondary outcomes

  1. PSA Response in the Standard Treatment Arm and Experimental Treatment Arm

    PSA response measured according to Prostate Cancer Working Group 2 (PCWG2). The study was terminated after only 9 patients enrolled, 5 to the standard of care docetaxel/prednisone arm and 4 to experimental docetaxel/prednisone/enzalutamide arm.

    Time frame: Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), Day 231, and every 21 days through study completion (an average of 1 year)

  2. Overall Survival

    Time frame: At both 1 year and 2 years from treatment start

Other outcomes

  1. Quality of Life (QOL)

    Time frame: Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), Day 231 and every 21 days through study completion (an average of 1 year)

  2. Circulating Tumor Cells (CTCs)

    Time frame: Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), and every 63 days through study completion (an average of 1 year)

  3. Analysis of Androgen Receptor Splice Variant

    Time frame: Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), and every 63 days through study completion (an average of 1 year)

07

Results

Posted Mar 12, 2021

Participant flow

Participant flow — Overall Study
MilestoneDocetaxel/PrednisoneDocetaxel/Prednisone + Enzalutamide
Started54
Completed54
Not completed00

Outcome measures

PrimaryProgression-free Survival (Radiographic or Per PCWG2 Criteria)

The primary endpoint of the study is progression-free survival (PFS), defined as the time from randomization to disease progression. Progression will be evaluated using a combination of RECIST and Prostate Cancer Working Group 2 guidelines.

Time frame:
1 year
Reported as:
Count of participants · Participants
Progression-free Survival (Radiographic or Per PCWG2 Criteria)
ParticipantsDocetaxel/PrednisoneDocetaxel/Prednisone + Enzalutamide
Progression-free Survival (Radiographic or Per PCWG2 Criteria)00
Statistical analysis
  • Docetaxel/Prednisone · Chi-squared · p = 0.6761 · Log-rank test: 0.6761
SecondaryPSA Response in the Standard Treatment Arm and Experimental Treatment Arm

PSA response measured according to Prostate Cancer Working Group 2 (PCWG2). The study was terminated after only 9 patients enrolled, 5 to the standard of care docetaxel/prednisone arm and 4 to experimental docetaxel/prednisone/enzalutamide arm.

Time frame:
Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), Day 231, and every 21 days through study completion (an average of 1 year)
Reported as:
Count of participants · Participants
PSA Response in the Standard Treatment Arm and Experimental Treatment Arm
ParticipantsDocetaxel/PrednisoneDocetaxel/Prednisone + Enzalutamide
PSA Response in the Standard Treatment Arm and Experimental Treatment Arm23
SecondaryOverall Survival
Time frame:
At both 1 year and 2 years from treatment start
Reported as:
Count of participants · Participants
Overall Survival
ParticipantsDocetaxel/PrednisoneDocetaxel/Prednisone + Enzalutamide
Overall Survival24
Other pre-specifiedQuality of Life (QOL)
Time frame:
Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), Day 231 and every 21 days through study completion (an average of 1 year)

Results for this outcome have not been posted.

Other pre-specifiedCirculating Tumor Cells (CTCs)
Time frame:
Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), and every 63 days through study completion (an average of 1 year)

Results for this outcome have not been posted.

Other pre-specifiedAnalysis of Androgen Receptor Splice Variant
Time frame:
Baseline, Day 84 (C4D1), Day 147 (C7D1), Day 210 (C10D1), and every 63 days through study completion (an average of 1 year)

Results for this outcome have not been posted.

Adverse events

Collected over From treatment administration through 30 days after date of last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel/Prednisone3/5 (60%)2/5 (40%)5/5 (100%)
Docetaxel/Prednisone + Enzalutamide0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventDocetaxel/PrednisoneDocetaxel/Prednisone + Enzalutamide
Muscle weakness lower limbMusculoskeletal and connective tissue disorders1/50/4
Atrial fibrillationCardiac disorders1/50/4
Most frequent other events
Showing 10 of 42
Most frequent other events
EventDocetaxel/PrednisoneDocetaxel/Prednisone + Enzalutamide
FatigueGeneral disorders5/54/4
NauseaGastrointestinal disorders4/52/4
AnorexiaMetabolism and nutrition disorders4/50/4
AlopeciaSkin and subcutaneous tissue disorders3/53/4
VomitingGastrointestinal disorders3/51/4
Peripheral sensory neuropathyNervous system disorders2/52/4
AnemiaBlood and lymphatic system disorders1/52/4
Peripheral motor neuropathyNervous system disorders2/51/4
MyalgiaMusculoskeletal and connective tissue disorders2/50/4
DiarrheaGastrointestinal disorders1/51/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Docetaxel/PrednisoneDocetaxel/Prednisone + EnzalutamideTotal
<=18 years000
Between 18 and 65 years224
>=65 years325
Age, Continuous
Age, Continuous(years)Docetaxel/PrednisoneDocetaxel/Prednisone + EnzalutamideTotal
Mean68.2 (55 to 84)67.25 (58 to 79)67.78 (55 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel/PrednisoneDocetaxel/Prednisone + EnzalutamideTotal
Female000
Male549
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Docetaxel/PrednisoneDocetaxel/Prednisone + EnzalutamideTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American224
White325
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Docetaxel/PrednisoneDocetaxel/Prednisone + EnzalutamideTotal
United States549
08

Study locations

5 sites
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • Decatur Memorial Hospital
    Decatur, Illinois 62526, United States
  • NorthShore University HealthSytem - Kellogg Cancer Center
    Evanston, Illinois 60201, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Univesity of Wisconsin
    Madison, Wisconsin 53705, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Aug 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2021, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2016
First posted
Feb 18, 2016
Start
Feb 2016
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Results first posted
Mar 12, 2021
Last update
Apr 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02685267
Lead sponsor
Prostate Cancer Clinical Trials Consortium
Responsible party
Sponsor
First posted
Feb 18, 2016
Start date
Feb 2016
Primary completion
Aug 2017
Completion
Aug 2017
Results posted
Mar 12, 2021
Last update
Apr 9, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion